Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About Protex
A Brief History of the Company
Protex Healthcare was incorporated in the United Kingdom in 1999 with the aim of developing Vacutex™, our unique capillary action wound dressing.
Our main product, Vacutex™, has been carefully developed and protected as part of a wider portfolio of wound management products over the past 15 years, and is now an internationally recognised solution for advanced wound care. The product was developed for patients with difficult to heal wounds, and is to be used by wound care specialist practitioners.
Following a three-year development period up to 2002, which included a large multi-centred random clinical trial and an independent audit, Vacutex™ was immediately accepted into the UK NHS reimbursement regime under a newly created separate reimbursement category. Market research amongst nurses inside and outside UK has shown in 2012-2014 that there was a growing need for a product like Vacutex, in the field of chronic and difficult to heal wounds. This still reflects its innovative and unique stature as a leading global wound management solution.
Since January 2015 and due to a change in ownership, Protex Healthcare has restarted its development and manufacturing processes, in particular in the field of difficult to heal wounds.
Mission and Vision
Protex Healthcare aims to further develop, manufacture and market a restricted range of highly specialised advanced wound care products for use in growing and specialised niche markets all over the world. The products are all developed in cooperation with nurses in their everyday practise, and are backed up with significant educational support towards our users (specialised wound care nurses and other wound care professionals in both hospitals as well as home care settings).
All our products aim to improve the quality and speed of wound healing and as well as the quality of life of our patients, in the meantime reducing both total nursing time and total care costs for patients, hospitals and governments.
Some of our major areas of focus are the treatment of difficult to heal wounds, such as DFU, VLU, pressure sores and dehisced wounds as well as several kinds of ulcers.
If this is the same "Protex" that make the sleeve for the Actipatch on CVS shelves, they may have just found the way to make a combo product.
You were all out yesterday
CVS to buy Aetna
(Reuters) - Health insurer Cigna Corp's (CI.N) $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
Wall Street analysts had expected antitrust approval as the companies have little overlap in their businesses. The decision bodes well for the pending U.S. antitrust review of CVS Health Corp's (CVS.N) proposed $69 billion acquisition of health insurer Aetna Inc (AET.N).
Maybe Aetna can cover Actipatch lol
That would be perfect, Art
Business
Teva Migraine Drug Wins FDA Approval, Bolstering Turnaround Plan
Yaacov Benmeleh Yaacov Benmeleh 4 hours ago
Teva Pharmaceutical Industries Ltd. won U.S. regulatory approval to sell a new treatment for migraines -- a key element of the company’s turnaround strategy. The U.S. Food and Drug Administration approved Ajovy, an injection in monthly and quarterly doses to treat migraines for adults, the Israeli drugmaker said in a statement late Friday. More than 36 million people in the U.S. suffer from these debilitating episodes, and the medicine could generate around $500 million of sales by 2022, according to analyst estimates compiled by Bloomberg. ...
Now lets have a treatment that requires no drugs. I wonder where that would come from?
Not making fun of him, it's pointing out a negative for the company. When you have a receptionist, you wouldn't want her to be hard to understand or be disheveled looking, I'm sorry to say that him being hard to understand looks bad for the company. You don't see commercials out there that leave you wondering what they said.